<DOC>
	<DOCNO>NCT01673529</DOCNO>
	<brief_summary>A two part , randomize , double-blind , placebo control study investigate effect topical dos SB705498 healthy volunteer .</brief_summary>
	<brief_title>Investigation Topical SB705498 Healthy Volunteers</brief_title>
	<detailed_description>This study two part , randomize , double-blind , placebo control study investigate effect topical dos SB705498 capsaicin , histamine , cowhage response healthy volunteer . Part A designed establish whether topical formulation capable deliver SB705498 propose site action , select appropriate dose Part B . Part B examine effect SB705498 pruritus initiate histaminergic non-histaminergic pathway , use two different challenge agent ; histamine cowhage . This may provide important information role TRPV1 pruritus therapeutic potential SB705498 .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<criteria>Healthy Caucasian volunteer age 18 65 year age inclusive , time signing informed consent . Healthy subject define individual take regular medication free clinically significant illness disease determine medical history ( include family history ) , physical examination , 12lead ECG , laboratory study , test specify protocol . Subject ability read , comprehend , record information require protocol , willing able provide sign dated write informed consent prior study participation , include compliance requirement restriction list consent form . Non smoker smoke used nicotine contain product minimum period 6 month prior screen visit . Subject must score great 40 COVAS scale 0100 itch induce cowhage histamine screen show flare response capsaicin measure LDI scan . Is willing avoid UV exposure . i.e . use Sun bed sunbathe 7 day prior screen , throughout study week last dose . Subjects require treatment photosensitizing drug ( e.g , tetracycline , thiazide , fluoroquinolones , phenothiazine , sulfonamide ) withdrawn . Subjects must also willing use sunscreen SPF30 volar surface forearm week last dose . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) great 40 MlU/ml estradiol le 40 pg/ml ( le 147 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method protocol wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . ] ; Childbearing potential agrees use one contraception method list protocol . Female subject willing participate study must agree use contraception screen visit 15 day postlast treatment administration . Male subject must agree use one contraception method list protocol . For male subject willing participate study criterion must follow time screen visit 15 day postlast treatment BMI within range 19.0 32.0 kg/m2 ( inclusive ) . AST ALT le 2xULN ; alkaline phosphatase bilirubin less equal 1.5xULN ( isolate bilirubin great 1.5xULN acceptable bilirubin fractionate direct bilirubin . QTcB QTcF le 450 msec . Note initial QTc value prolong , ECG repeat two time ( 5 minute ECG reading ) average three QTc value use determine eligibility . Suffers skin infection inflammation forearm , arm skin irregularity may opinion investigator interfere study assessment ( e.g . nevus , tattoo ) . The subject suffers eczema , psoriasis acute chronic dermatological problem , opinion investigator likely interfere study assessment Any subject localised sunburn area treat part study . History regular alcohol/drug consumption within 6 month study . Regular alcohol consumption define : average weekly intake great 21 unit male great 14 unit female . One unit equivalent 8 g alcohol : halfpint ( approximately 240 ml ) beer , one glass ( 125 ml ) wine one ( 25 ml ) measure spirit . A positive prestudy drug/alcohol screen screen visit . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . The subject participate clinical trial result exposure four new chemical entity within 12 month prior first dose day receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Unable refrain use prescription nonprescription drug . Refer protocol detail . History sensitivity study medication SB705498 , challenge agent component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period follow completion study . Lactating female . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive test HIV antibody . Excessive caffeine drinker ( approximately 5 cup day ) subject unable commit refrain caffeinecontaining product 24hrs prior assessment visit whilst present unit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pruritus</keyword>
	<keyword>TRPV1</keyword>
	<keyword>Cowhage</keyword>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Capsaicin</keyword>
	<keyword>Itch</keyword>
	<keyword>Histamine</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>SB705498</keyword>
	<keyword>Clinical</keyword>
</DOC>